Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068004 | 0.83 | HTR5A (0.35) | HTR5A | |
| SCHEMBL7071475 | 0.83 | HTR5A (0.35) | HTR5A | |
| SCHEMBL7069732 | 0.82 | KMT2A (0.35) | HTR5A | |
| SCHEMBL7071984 | 0.81 | HTR5A (0.37) | HTR5A | |
| SCHEMBL7067483 | 0.77 | ABCC8 (0.31) | HTR5A | |
| SCHEMBL7067583 | 0.75 | — | — | |
| SCHEMBL8583089 | 0.74 | HTR5A (0.36) | HTR5A | |
| SCHEMBL8587012 | 0.74 | NOX1 (0.37) | HTR5A | |
| SCHEMBL7077783 | 0.73 | HTR5A (0.33) | HTR5A | |
| SCHEMBL8583882 | 0.71 | HTR5A (0.39) | HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003105896-A1 | COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | claimed |
| WO-2003045954-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045955-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | claimed |
| WO-2002000222-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | claimed |
| WO-2002000223-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | claimed |
| WO-2003105896-A1 | COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003045954-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003045955-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002000222-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |